EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Differences in anti‐amyloid therapy eligibility assessment based on use of the SWI versus GRE sequence

Camilo Bermudez, Jay J. Pillai, Brian J. Burkett, Jennifer S. McDonald, Derek R. Johnson, Heather J. Wiste, Stephen D. Weigand, Clifford R. Jack, Prashanthi Vemuri, Ronald C. Petersen, Jonathan Graff‐Radford, Vijay K. Ramanan, Petrice M. Cogswell

Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring · 2026-10 · 18 (4)

DOI: 10.1002/dad2.70524 ↗
AbstractBibliografische Angaben

Abstract

Abstract Introduction The number of microhemorrhages (mHs) increases risk of amyloid‐related imaging abnormalities (ARIAs) in those undergoing anti‐amyloid treatments for Alzheimer's disease. It is unclear whether using different magnetic resonance imaging (MRI) sequences to detect mH would alter treatment decisions. Methods We retrospectively analyzed 55 adults (mean age 72.1 ± 7.1 years) evaluated for cognitive concerns who had MRI exams including both susceptibility‐weighted imaging (SWI) and gradient echo (GRE) sequences. Three neuroradiologists independently identified and then reached consensus on mH detection. Participants were classified into mH burden categories (none, 1, 2–4, ≥ 5). Results Readers identified 83 mHs (mean 1.51) on SWI versus 54 (mean 0.98) on GRE. Burden categories agreed in 34 (61.8%) participants, was higher on SWI in 17 (30.9%) participants, and higher on GRE in 4 (7.3%) participants, Conclusions Readers on average identified more mHs on SWI than GRE, altering risk categories. Prospective studies are needed to establish SWI‐based safety thresholds for anti‐amyloid therapies.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →